



**BRAWN**



A3DA0

CIN NO.: L74899DL1985PLC022468

05<sup>th</sup> August, 2022

The General Manager  
The Department of Corporate Services,  
BSE Limited, 25<sup>th</sup> Floor,  
Phiroze Jeebhoy Towers,  
Dalal Street, Mumbai -400001

BSE Scrip Code: 530207  
Scrip ID: BRAWN

**Sub: Outcome of Board Meeting and Submission of unaudited Financial Results for the quarter 30.06.2022.**

Dear Sir/ Ma'am,

We wish to inform you that pursuant to the Regulation 30 and 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and any other applicable provisions, if any, the Board of Directors of the Company, at its meeting held on today i.e. 05<sup>th</sup> August, 2022, inter-alia considered and approved/noted the following:

1. Standalone Un-audited Financial Results along with Limited Review Report by the Company's Statutory Auditor for the quarter ended 30<sup>th</sup> June, 2022, a copy of which is enclosed herewith.
2. Appointed Ms. Pooja Pandey as the Chief Financial Officer of the Company. Brief profile is enclosed as Annexure.

We wish to further inform you that the meeting of the Board of directors commenced at 03:00 PM and concluded at 04:00 PM.

This is for your kind information and record.

Thanking You.

For and on behalf of  
**BRAWN BIOTECH LIMITED**

  
Priyanka Sharma  
Company Secretary & Compliance Officer



Encl: As above

**BRAWN BIOTECH LTD.**  
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: [solutions@brawnbiotech.com](mailto:solutions@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462  
Email: [solutions@brawnbiotech.com](mailto:solutions@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

*...for better life*



# BRAWN



607DE

CIN NO.: L74899DL1985PLC022468

<b>BRAWN BIOTECH LIMITED</b> CIN:L74899DL1985PLC022468 REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024				
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2022				
Sr. No.	Particulars	Quarter Ended		Rs. In Lacs
		30-Jun-22	31-Mar-22	Year Ended
		Un-audited	Audited	30-Jun-21
				31-Mar-22
				Audited
<b>1</b>	<b>Revenue from operations</b>			
	Revenue from operations	340.21	288.71	112.79
	Other Income	0.01	(8.83)	0.14
	<b>Total Revenue</b>	<b>340.22</b>	<b>279.88</b>	<b>112.94</b>
<b>2</b>	<b>Expenses</b>			
<b>a</b>	Cost of material consumed	-	-	-
<b>b</b>	Purchase of stock-in-trade	191.90	378.50	40.16
<b>c</b>	Change in inventories of finished goods, work in progress and stock in trade	49.31	(208.33)	(2.66)
<b>d</b>	Employee Benefit expenses	35.55	45.03	54.02
<b>e</b>	Depreciation and amortisation expenses	2.32	2.00	0.90
<b>f</b>	Finance Cost	0.03	0.51	0.26
<b>g</b>	Other expenses	45.73	46.51	42.07
	<b>Total Expenses</b>	<b>324.84</b>	<b>264.22</b>	<b>134.74</b>
<b>3</b>	<b>Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)</b>	<b>15.38</b>	<b>15.66</b>	<b>(21.81)</b>
<b>4</b>	<b>Other Income</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit from ordinary activities before exceptional items (3-4)</b>	<b>15.38</b>	<b>15.66</b>	<b>(21.81)</b>
<b>6</b>	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>7</b>	<b>Profit from ordinary activities before tax (5-6)</b>	<b>15.38</b>	<b>15.66</b>	<b>(21.81)</b>
<b>8</b>	<b>Tax Expenses</b>	<b>2.26</b>	<b>(47.34)</b>	<b>(47.34)</b>
<b>9</b>	<b>Profit (Loss) for the period from continuing operations (7-8)</b>	<b>13.12</b>	<b>63.00</b>	<b>(21.81)</b>
<b>10</b>	<b>Profit/(loss) from discontinuing operations</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>11</b>	<b>Tax expense of discontinuing operations</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>12</b>	<b>Profit/(loss) from Discontinuing operations (after tax) (10-11)</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13</b>	<b>Profit (Loss) for the period (9+12)</b>	<b>13.12</b>	<b>63.00</b>	<b>(21.81)</b>
<b>14</b>	<b>Other Comprehensive Income</b>	<b>(0.31)</b>	<b>1.75</b>	<b>(0.56)</b>
	<b>Total Comprehensive Income</b>	<b>12.81</b>	<b>64.75</b>	<b>(22.37)</b>
<b>15</b>	<b>Details of equity share capital</b>	<b>300.03</b>	<b>300.03</b>	<b>300.03</b>
	Paid-up equity share capital			
	Face value of equity share capital			
<b>16</b>	<b>Reserve excluding Revaluation Reserve</b>			
<b>17</b>	<b>Earnings per share</b>			
<b>i</b>	Basic earnings per share	0.43	2.16	(0.75)
<b>ii</b>	Diluted earnings per share	0.43	2.16	(0.75)

**NOTES :-**

- Results for the quarter ended on 30th June, 2022 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 5th August, 2022.
- The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, intangible assets, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
- The Statutory Auditors carried out the limited review for quarter ended 30th June, 2022. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 30.06-2022 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

*(Signature)*  
Brij Raj Gupta  
Director  
DIN NO. 00974969  
Date: 05-08-2022  
Place: Delhi

**BRAWN BIOTECH LTD.**  
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

*... for better life*



To,  
**The Board of Directors of  
Brawn Biotech Limited**

We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the period ended 30<sup>th</sup> June 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

**For Rajiv Udai & Associates  
Chartered Accountants  
Firm Registration No. 018764N**

  
**Rajeev Jain  
Partner  
Membership No. 099767  
UDIN: 22099767AOHYZA2717**



**Place: Delhi  
Date: 05-08-2022**



**BRAWN**



3AD9D

CIN NO.: L74899DL1985PLC022468

**ANNEXURE**

05th August, 2022

The General Manager  
The Department of Corporate Services,  
BSE Limited, 25th Floor,  
Phiroze Jeejebhoy Towers,  
Dalal Street, Mumbai -400001

**Sub: Brief profile of Chief Financial Officer of the Company**

Dear Mam/Sir,

With reference to the subject to the mentioned above, please find below the profile of CFO

<b>Name of the CFO</b>	Ms. Pooja Pandey
<b>Effective date of Appointment</b>	05.08.2022
<b>Terms of appointment</b>	Appointed as the Chief Financial Officer of the Company
<b>Brief Profile</b>	Ms. Pooja Pandey is a qualified member of Institute of Chartered Accountants of India (ICAI) having experienced with a broad set of skills involving Finance, Accounting and Taxation.
<b>Disclosure of relationships with Directors/Key Managerial Personnel or their relatives</b>	Ms. Pooja Pandey is not related to any of the Directors or Key Managerial Personnel or any of their relatives.

Kindly take the above information on record.

Thanking you.

For and on behalf of  
Brawn Biotech Limited

  
Priyanka Sharma  
Company Secretary & Compliance Officer



**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129515331  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana , INDIA Tel: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

*... for better life*